Clinical outcome of gemcitabine/S-1 combination therapy for advanced pancreatic cancer.
Pancreas (impact factor: 2.39). 05/2008; 36(3):327-8. DOI:10.1097/MPA.0b013e31815cc464 pp.327-8
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.